Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 05 Jun 2021 Results of a post hoc analysis assessing the patient-reported outcomes in RA patients from Asia treated with GLM in phase-3 trials (GO-FORWARD, NCT01248780) presented at the 22nd Annual Congress of the European League Against Rheumatism
- 15 Jun 2013 Results presented at the 14th Annual Congress of the European League Against Rheumatism.
- 09 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.